Novartis AG

NYSE:NVS Stock Report

Market Cap: US$291.3b

Novartis Management

Management criteria checks 2/4

Novartis' CEO is Vas Narasimhan, appointed in Feb 2018, has a tenure of 8.42 years. total yearly compensation is $19.17M, comprised of 12.5% salary and 87.5% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth $68.16M. The average tenure of the management team and the board of directors is 4.3 years and 6.4 years respectively.

Key information

Vas Narasimhan

Chief executive officer

US$19.2m

Total compensation

CEO salary percentage12.50%
CEO tenure8.4yrs
CEO ownership0.02%
Management average tenure4.3yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 04

Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts

Summary Novartis is downgraded from 'Strong Buy' to 'Hold' due to significant generic erosion impacting Q1 2026 sales and future growth outlook. Q1 2026 sales declined 5% [cc] to $13.1B, with ENTRESTO dropping 46% and ZOLGENSMA down 12%, offset by strong growth in KISQALI [55%] and PLUVICTO [70%]. ITVISMA's European approval expands the SMA franchise to a broader patient group, while PLUVICTO's sNDA for mHSPC could drive future growth if approved. Full-year 2026 revenue guidance is for low single-digit percentage growth; upcoming 2H 2026 data readouts are critical for improving the mid- to long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Why Novartis Remains A 'Buy' After Beating Expectations Again

Summary At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluvicto, a medication for the treatment of prostate cancer, reached $351 million in the fourth quarter of 2024, an increase of 28.6% year-on-year. Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. In this article, dear Seeking Alpha readers, you'll know more about why I believe Novartis is an appealing stock for income-oriented investors. Read the full article on Seeking Alpha
Seeking Alpha • Feb 14

Novartis: Just What The Doctor Ordered

Summary Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield. Despite industry risks, Novartis' growth outlook remains positive, bolstered by a solid drug roster, pipeline, and exceptional balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Summary Novartis experienced a strong bull run in 2024 but saw a 13% pullback post Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 patent expirations for key drugs like Entresto, Promacta, and Tasigna triggered a sell-off. Novartis' robust pipeline and new product launches are expected to offset losses from patent expirations, supporting long-term growth and a "Buy" rating. At prices below $100 per share, Novartis stock is an attractive buy, but investors need patience due to potential short-term revenue declines. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

Novartis: Time To Increase

Summary Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

What To Expect When Novartis Reports Q3 2024 Results

Summary Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third quarter. Recent litigation updates on Entresto were negative and Novartis continues to anticipate a 2H 2025 generic launch. No major new pipeline updates are expected next week. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Vas Narasimhan's remuneration changed compared to Novartis's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$14b

Dec 31 2025US$19mUS$2m

US$14b

Sep 30 2025n/an/a

US$14b

Jun 30 2025n/an/a

US$14b

Mar 31 2025n/an/a

US$13b

Dec 31 2024US$16mUS$2m

US$12b

Sep 30 2024n/an/a

US$12b

Jun 30 2024n/an/a

US$10b

Mar 31 2024n/an/a

US$9b

Dec 31 2023US$16mUS$2m

US$9b

Sep 30 2023n/an/a

US$7b

Jun 30 2023n/an/a

US$7b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$12mUS$2m

US$6b

Sep 30 2022n/an/a

US$21b

Jun 30 2022n/an/a

US$22b

Mar 31 2022n/an/a

US$24b

Dec 31 2021US$12mUS$2m

US$23b

Sep 30 2021n/an/a

US$10b

Jun 30 2021n/an/a

US$9b

Mar 31 2021n/an/a

US$8b

Dec 31 2020US$12mUS$2m

US$8b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$7b

Dec 31 2019US$12mUS$2m

US$7b

Compensation vs Market: Vas's total compensation ($USD19.17M) is above average for companies of similar size in the US market ($USD14.46M).

Compensation vs Earnings: Vas's compensation has increased by more than 20% in the past year.

CEO

Vas Narasimhan (50 yo)

8.4yrs
Tenure
US$19,170,008
Compensation

Dr. Vasant Narasimhan, also known as Vas, is Director of Anthropic PBC from April 2026. Dr. Narasimhan is Chief Executive Officer of Novartis International AG from 2018. He serves as Chief Executive Office...

Leadership Team

NamePositionTenureCompensationOwnership
Vasant Narasimhan
Chief Executive Officer8.4yrsUS$19.17m0.023%
$ 68.2m
Victor Bulto
President of US4.3yrsUS$7.26m0.0019%
$ 5.6m
Patrick Horber
President of International2.6yrsUS$7.11m0.0034%
$ 10.0m
Mukul Mehta
Chief Financial Officerless than a yearno datano data
Steffen Lang
President of Operations4.3yrsUS$4.17m0.0067%
$ 19.6m
Paul Penepent
Head of Group Financial Reporting and Accountingno datano datano data
Sloan Simpson
Global Head of Investor Relations2.3yrsno datano data
Karen Hale
Chief Legal & Compliance Officer5.2yrsUS$4.16m0.0032%
$ 9.2m
Robert Kowalski
Chief People & Organization Officer4.8yrsUS$3.45m0.0012%
$ 3.6m
Evan Beckman
Global Head of Translational Medicine at Novartis Institute for BioMedical Researchno datano datano data
Paul Spittle
Head of Global Product & Portfolio Strategy Pharmano datano datano data
Renaud Capdeville
Global Program Head for Hematologic Malignanciesno datano datano data
4.3yrs
Average Tenure
56yo
Average Age

Experienced Management: NVS's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Simon Moroney
Independent Vice Chairman of the Board6.4yrsUS$580.68k0.00043%
$ 1.3m
Daniel Vasella
Honorary Chairmanno dataUS$3.34mno data
Bridgette Heller
Independent Non-Executive Director6.4yrsUS$542.81k0.00043%
$ 1.3m
François van Houten
Independent Non-Executive Director9.4yrsUS$534.39k0.0010%
$ 3.0m
Ton Buechner
Independent Non-Executive Director10.4yrsUS$536.25k0.0014%
$ 4.2m
Ana de Pro Gonzalo
Independent Non-Executive Director4.3yrsUS$492.31k0.00022%
$ 640.9k
Giovanni Caforio
Independent Chairman of the Board1.3yrsUS$3.71mno data
Patrice Bula
Lead Independent Director7.4yrsUS$522.50k0.00073%
$ 2.1m
John Young
Non-Executive Independent Director3.3yrsUS$534.39k0.00011%
$ 320.4k
Nancy Andrews
Independent Non-Executive Director11.4yrsUS$454.44k0.00065%
$ 1.9m
Elizabeth Doherty
Independent Non-Executive Director10.4yrsUS$568.05k0.00091%
$ 2.7m
Elizabeth McNally
Independent Director1.3yrsUS$336.62kno data
6.4yrs
Average Tenure
65.5yo
Average Age

Experienced Board: NVS's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 05:33
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novartis AG is covered by 55 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research